SYNEURX INTERNATIONAL TAIWAN CORP.
SyneuRx is a mental health care company that is developing potential treatments for schizophrenia, dementia, and depression. They offer treatment for schizophrenia, depression, and dementia.
SYNEURX INTERNATIONAL TAIWAN CORP.
Industry:
Biopharma Clinical Trials Pharmaceutical
Founded:
2013-01-01
Address:
Taipei, T'ai-pei, Taiwan
Country:
Taiwan
Website Url:
http://www.syneurx.com
Total Employee:
1+
Status:
Active
Contact:
886-2-7742-2699
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics SSL By Default Global Site Tag
Similar Organizations
Arcus Biosciences
Arcus Biosciences is a biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.
Ascentage Pharma
Ascentage is a clinical-stage biopharmaceutical company that develops drugs for the treatment of cancer.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Oppilan Pharma
Oppilan Pharma is a biopharmaceutical company that develops novel small molecule therapeutics for the treatment of autoimmune diseases.
Halo Labs
Halo Labs is a biotechnology company that specializes in analytical instrumentation and biopharma.
PRD Therapeutics
PRD Therapeutics is a pharmaceutical company that develops medicines for different metabolic diseases.
Tanvex BioPharma
Tanvex BioPharma is a biopharmaceutical company that provides drug manufacturing, sales, and distribution services.
Investors List
Taiwania Capital Management Corporation
Taiwania Capital Management Corporation investment in Post-IPO Equity - SyneuRx International Taiwan Corp.
Official Site Inspections
http://www.syneurx.com
- Host name: h117-203-67-103.seed.net.tw
- IP address: 203.67.103.117
- Location: Taiwan
- Latitude: 23.5
- Longitude: 121
- Timezone: Asia/Taipei
More informations about "SyneuRx International Taiwan Corp."
About – SyneuRx
SyneuRx will make all potential new treatments available worldwide, eliminating inequity in health due to access. ... Ms. Chuang is also the chief director of the Awakening Foundation, a non-governmental organization focused on gender …See details»
SyneuRx
Apr 26, 2024 SyneuRx is currently conducting clinical development of two COVID-19 treatments— Pentarlandir® in oral capsule form and Airnecflu® in an inhaled form. Pentarlandir® completed US Phase 2 clinical trial in June 2022 …See details»
SyneuRx Neuroscience - Crunchbase Company Profile …
SyneuRx Neuroscience is new drug development. is a global CRO and consultation firm that engages in activities related to the biopharmaceutical …See details»
心悅生醫股份有限公司 民國一一二年度 年 報 - syneurx.com
電子郵件信箱：[email protected] 代理發言人 姓 名：顏怡真 職 稱：財會協理 電 話：(02) 7742-2699 投資人專線：(02) 7742-2699 電子郵件信箱：[email protected] …See details»
SyneuRx - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 6, 2025 SyneuRx - Company developing a novel class of drugs (under late stage trials) for Schizophrenia. Public Company. Raised funding from 2 investors. SyneuRx has 109 competitors.See details»
SyneuRx International Taiwan 2025 Company Profile: Overview ...
May 5, 2020 SyneuRx International Taiwan General Information Description. SyneuRx International (Taiwan) Corp is a bio-medical company. The company is engaged in the …See details»
What we do - SyneuRx
SyneuRx is investigating novel therapies for these unmet medical needs. When successfully developed with the research trials, SyneuRx’ investigational therapy will provide those with …See details»
SyneuRx Neuroscience - Overview, News & Similar companies
SyneuRx Neuroscience. Manufacturing · California, United States · <25 Employees. View Company Info for Free. About. Headquarters 16501 Ventura Blvd Ste 400, Encino, …See details»
Portfolios-SyneuRx - Taiwania Capital
SyneuRx was founded in 2013 and is currently developing revolutionary new drugs. In the field of central nervous system, we prioritize schizophrenia, severe depression, and dementia. We …See details»
SyneuRx International (Taiwan) Corp. - discovery.patsnap.com
Feb 19, 2023 SyneuRx International (Taiwan) Corp. is a company that provides Breakthrough therapy, Attention deficit hyperactivity disorder, Mental illness and more. SyneuRx …See details»
心悅(SyneuRx) 股票代號:6575-台灣上市上櫃公司
心悅(SyneuRx) 股票代號:6575 心悅生醫股份有限公司,地址:新北市汐止區新台五路一段99號20F-8,統編:54179072,電話:02-77422699,傳真:02-26972629,Mail:[email protected],網 …See details»
Synxyrin - Drug Targets, Indications, Patents - Synapse
SyneuRx has no obligation to amend or update this press release to respond to any events that occur after the publication of this article. New drug development takes a long time and high …See details»
Sodium benzoate - SyneuRx - AdisInsight
26 Oct 2023 SyneuRx International (Taiwan) corp terminates a phase IIb/III trials for Schizophrenia (In adolescents, Adjuvant therapy) in USA and Taiwan (PO) (NCT01908192) …See details»
TRPMA 台灣研發型生技新藥發展協會 - TRPMA 官方網站
心悅生醫創立於2013年，由約翰霍普金斯大學神經科學博士、哈佛醫學院助教授、現任UCLA醫學院教授的蔡果荃博士領導，他曾發表上百篇論文，被引用次數超過13500次。心悅是生技新藥 …See details»
心悅生醫宣布與馬光保健控股股份有限公司簽署合作備忘錄 – …
2022年9月27日，專注於開發創新藥物治療 covid-19 、多種中樞神經系統疾病的心悅生醫(tpex:6575)，今天宣布與馬光保健控股股份有限公司(tpex:4139，以下簡稱馬光控股)簽署合作 …See details»
SNG 12 - AdisInsight - Springer
23 Sep 2022 SyneuRx International submits IND application to the US FDA for a planned phase III trial in Depressive disorders and Suicidal ideation, prior to September 2022 (SyneuRx …See details»
Refractory Schizophrenia - SyneuRx
In refractory schizophrenia, the symptoms cannot be improved much by the antipsychotic medications and patients with refractory schizophrenia are taking the last line medication of …See details»
SND 4 - AdisInsight
Dec 6, 2024 SND 4 is a small molecule being developed by SyneuRx International for add-on treatment of adult schizophrenia. It acts as a D-amino acid oxidase (DAAO) SND 4 Next ... If …See details»
Trial-Refractory Schizophrenia Study-Tw – SyneuRx
The Refractory Schizophrenia Study is one of SyneuRx’s efforts to bring new treatment options to schizophrenia patients. It is a late (IIb/III) phase clinical study to examine and confirm the …See details»
心悅生醫 SND13 NaBen©精神分裂症 IIb/III期合併臨床試驗首三位 …
May 11, 2017 心悅生醫今天宣布其 snd13精神分裂症iib/iii期 合併臨床試驗短期內已經篩選11 位受試者，其中三位正式進入隨機分配治療階段。See details»